Notícias e Atividades da Cellectis

Cellectis é uma empresa listada sob o símbolo CLLS (FR).

Veja o organograma con seus 30 executivos principais

Biografias mais buscadas da Cellectis

• André Choulika, Chief Executive Officer and Director
• Laurent Arthaud, Director
• Axel-Sven Malkomes, Director

Recentes movimentos de executivos em Cellectis

• Hillary Hillmann, Director, Quality Control, deixou a Companhia  (Notícia publicada em 28 de abril de 2026).

Criar um alerta
para seguir os movimentos de executivos da Cellectis.

Cellectis possui 2.428 concorrentes concorrentes Lonza (Suíça), Vertex Pharmaceuticals (Estados Unidos) e Eurofins (Luxemburgo).

Popular M&A news in Biotecnologia

• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado em 17 de julho de 2026).
• GSK adquiriu Nuvalent (publicado em 17 de julho de 2026).
• Clearside Biomedical has gone out of its bankruptcy protection  (publicado em 15 de julho de 2026).

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Robert Gould - Board Member da Fulcrum Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Cellectis

• Cellectis Appoints William Monteith as Senior Vice President U.S. Manufacturing | Cellectis
• Cellectis Reports Financial Results for 3rd Quarter and First Nine Months 2018 | Cellectis
• CAR-T Pioneer Dr. Stephan A. Grupp to Join Cellectis Clinical Advisory Board | Cellectis
• Calyxt Appoints CEO, Jim Blome, Former President & CEO of Bayer CropScience LP | Cellectis
• Calyxt Names Biotech Veteran and Board of Directors Member Dr. Yves J. Ribeill as Interim CEO | Cellectis
• Cellectis Appoints Stefan Scherer M.D., Ph.D., as Senior Vice President Clinical Development and Deputy Chief Medical Officer | Cellectis
• Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2018 | Cellectis
• Cellectis S.A. Reports Results from Annual General Meeting Held on June 26, 2018 | Cellectis
• Cellectis Publishes Novel Methods to Improve the Clinical Use of Chimeric Antigen Receptor T-Cell Therapy in Scientific Reports | Cellectis
• Shareholders’ General Meeting of June 26, 2018 | Cellectis
• View more press releases Close

Redes sociais sobre Cellectis

• Cellectis na Wikipedia, Google News e Yahoo Finance
• Cellectis na LinkedIn, X (Twitter) e YouTube